New injection trial targets rare blood cancer symptoms
Disease control
Recruiting now
This study is testing whether canakinumab, an anti-inflammatory injection given every 3 weeks, can help control myelofibrosis. Researchers want to see if it reduces symptoms like fatigue and enlarged spleen, improves anemia, and is safe for patients. The trial is for adults with …
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC